RESUMEN
To explore the correlation between T lymphocytes and clinical severity in patients of COVID-19. A total of 183 COVID-19 patients were recruited in Shenzhen Third People's Hospital from January 11 to February 16, 2020. According to the clinical classification criteria, they were divided into severe group (46 cases) and non-severe (137cases). T lymphocyte counts, lymphocyte subpopulation, IL-6 levels, and clinical outcomes were compared between the two groups. Compared with the non-severe group, the lymphocyte count, T lymphocyte count, T lymphocyte percentage, CD4+ T lymphocyte count, CD4+ T lymphocyte percentage, CD8+ T lymphocyte count, and CD8+ T lymphocyte percentage were lower in the severe group (p < 0.05). Compared with the non-severe group, IL-6 were higher in the severe group (p < 0.05). Compared with admission, the T lymphocyte count, CD4+ T lymphocyte count, and CD8+ T lymphocyte count were significantly increased upon discharge in severe patients, non-severe patients and all patients. Multivariate Logsitic regression analysis showed CD4+ T lymphocyte count (OR −0.011;95% CI −0.041 to −0.001;p = 0.011), CD8+ T lymphocyte count (OR −0.14;95% CI −0.048 to −0.003;p = 0.013) were closely correlated with the clinical severity in patients of COVID-19. Multivariate Logsitic regression analysis also showed CD4+ T lymphocyte count (OR −0.012;95% CI −3.177 to 0.261;p = 0.021), CD8+ T lymphocyte count (OR −0.019;95% CI −5.852 to 0.115;p = 0.004) were independent predictors of disease progressing to the composite endpoint. Subgroup analysis for critically ill patients: The T lymphocyte count, CD4+ T lymphocyte count, and CD8+ T lymphocyte count remained low in the death patients. The T lymphocyte count, CD4+ T lymphocyte count, and CD8+ T lymphocyte count recovered soon in the discharged patients. In the event of COVID-19 infection, the T-lymphoid system is the primary activated immune system. The T lymphocytes, CD4+ T lymphocytes, CD8+ T lymphocytes continued to be low may be significantly related to the deterioration of the disease, and may indicate a poor prognosis. [ABSTRACT FROM AUTHOR] Copyright of European Journal of Inflammation (Sage Publications, Ltd.) is the property of Sage Publications, Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
RESUMEN
The worldwide pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in late December 2019 requires the urgent development of therapeutic options. So far, numerous studies have investigated and uncovered the underlying epidemiology and clinical characteristics of COVID-19 infections in order to develop effective drugs. Compared with antiviral small-molecule inhibitors, biotherapeutics have unique advantages such as few side effects by virtue of their high specificity, and thus can be rapidly developed for promising treatments of COVID-19. Here, we summarize potential biotherapeutics and their mechanisms of action, including convalescent plasma, therapeutic antibodies, peptides, engineered ACE2, interferons, cytokine inhibitors, and RNAi-based therapeutics, and discuss in depth the advancements and precautions for each type of biotherapeutics in the treatment of COVID-19.
RESUMEN
The ability of the human adaptive immune system to respond to antigens relies upon the tremendous diversity of T cell receptors (TCR) and B cell receptors (BCR). The entirety of an individual's BCRs, often referred to as an antibody repertoire, shapes the humoral immune system. Therefore, technologies to identify and characterize antibody repertoires are critical for understanding fundamental aspects of the development and maintenance of the humoral immune system. Recently, innovative methodologies and technologies devoted to high-throughput sequencing of antibody repertoires (Ig-Seq) have broadened the understanding of humoral immunity. This review provides an overview of the Ig-Seq pipeline from sample collection, library preparation, and sequencing, to data cleaning, sequence alignment, and high-level processing. Conventional and current strategies used in Ig-Seq are introduced in detail, including bulk BCR sequencing, heavy and light chain paired sequencing combined with proteomic or single B cell sequencing approaches, antigen-specific single B cell sequencing, and single-molecule sequencing. Applications of Ig-Seq are also discussed, including antibody diversity measurement, signatures associated with different populations, novel findings involved in the antibody repertoire development, and strategies of functional antibody discovery from antibody repertoires. Finally, the pitfalls and opportunities in the deep mining of antibody repertoires are discussed.